This Week in Oncology — Jun 18, 2026

Welcome to This Week in Oncology. This week we're covering 9 notable papers spanning major advances in multiple myeloma, the expanding role of artificial intelligence and proteomics in diagnostics, and key updates in solid tumor management. Let's dive in.
This week's papers:
• Towards autonomous medical artificial intelligence agents. — Nature 2026 (pubmed.ncbi.nlm.nih.gov/42310457)
• Development and validation of artificial intelligence-assisted volumetric response criteria in pleural mesothelioma (ARTIMES): a retrospective, multicohort, multicentre study. — The Lancet. Oncology 2026 (pubmed.ncbi.nlm.nih.gov/42309108)
• Management of Differentiated Thyroid Cancer. — The New England journal of medicine 2026 (pubmed.ncbi.nlm.nih.gov/42308485)
• Plasma proteomics improves thrombosis prediction in patients with cancer and identifies targetable IL-17-driven endothelial activation. — Science translational medicine 2026 (pubmed.ncbi.nlm.nih.gov/42308329)
• Donor bone marrow together with recipient regulatory T cells induces chimerism without irradiation in kidney transplantation. — Science translational medicine 2026 (pubmed.ncbi.nlm.nih.gov/42308328)
• Plasma proteomic signatures of cellular aging predict human disease. — Nature medicine 2026 (pubmed.ncbi.nlm.nih.gov/42297981)
• Aumolertinib with or without chemotherapy in EGFR-mutated advanced non-small-cell lung cancer (AENEAS2): an open-label, multicentre, randomised, controlled, phase 3 trial. — The Lancet. Oncology 2026 (pubmed.ncbi.nlm.nih.gov/42296979)
• Talquetamab-Daratumumab in Relapsed or Refractory Myeloma. — The New England journal of medicine 2026 (pubmed.ncbi.nlm.nih.gov/42294841)
• Mezigdomide, carfilzomib, and dexamethasone versus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma (SUCCESSOR-2): a phase 3, open-label, randomised controlled trial. — Lancet (London, England) 2026 (pubmed.ncbi.nlm.nih.gov/42289183)
Listen at AudioScholar (audioscholar.cc/episode/e367xrv6gt)